Presentation is loading. Please wait.

Presentation is loading. Please wait.

Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer  Jeffrey A. Borgia, PhD, Sanjib.

Published byJoshua Jackson Modified over 5 years ago

Similar presentations

Presentation on theme: "Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer  Jeffrey A. Borgia, PhD, Sanjib."— Presentation transcript:

1 Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer  Jeffrey A. Borgia, PhD, Sanjib Basu, PhD, L Penfield Faber, MD, Anthony W. Kim, MD, John S. Coon, MD, PhD, Kelly A. Kaiser-Walters, BS, Cristina Fhied, MS, Sherene Thomas, PhD, Omid Rouhi, MD, William H. Warren, MD, Philip Bonomi, MD, Michael J. Liptay, MD  Journal of Thoracic Oncology  Volume 4, Issue 3, Pages (March 2009) DOI: /JTO.0b013e abf Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Boxplots of biomarker candidates from the Random Forest analysis. Box and Whisker plots were generated for each individual biomarker in the final iteration of the Random Forest analysis. Designations on the abscissa: “0” refers to lymph node negative, whereas “1” refers to lymph node positive (both relative to pathologic stage). The extreme values are hidden. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e abf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Classification and Regression Tree for predicting preoperative nodal status in non-small cell lung cancer (NSCLC) patients. A binary ‘if-then’ set of decision rules is used to split the data into separate branches of the tree with each node of the tree displaying the appropriate analyte and threshold concentrations. Additional classifications continue to the left if the threshold is not met, and to the right if the value is equal to or exceeding this cutoff. The number of classifications (observations) are listed immediately below each terminal node, with each final arm labeled (0 = node negative; 1 = node positive). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e abf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Receiver operator characteristic curve for the most robust staging subpanel generated by the Random Forest analysis. Area under the curve = 0.94; Sensitivity = 88%; Specificity = 87%. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e abf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Boxplots of the 6-analyte biomarker panel for identifying preoperative nodal status with respect to extent of nodal station involvement. Boxplots for the 6-analytes comprising our most optimal panel for predicting lymph node involvement are represented with the node positive subjects subdivided according to either single or multiple nodal station involvement as a surrogate for total nodal involvement. (Mann-Whitney p-values: *, p = 0.011; **, p = 0.07; **, p = 0.012). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e abf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer  Jeffrey A. Borgia, PhD, Sanjib."

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters  Christopher W. Seder, MD, Andrew.

Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters  Christopher W. Seder, MD, Andrew.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis  María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis  María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,
Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee 

Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee 
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules  Christopher W. Seder, MD, John C. Kubasiak,

Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules  Christopher W. Seder, MD, John C. Kubasiak,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.
The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe  Yukinori Sakao,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe  Yukinori Sakao,
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Similar presentations

Ads by Google